Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Response Genetics provides BRAF mutational analysis technology to GSK
June 2010
SHARING OPTIONS:

LOS ANGELES—Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, has signed a non-exclusive license agreement with GlaxoSmithKline giving GSK certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase (B-raf), a protein involved in cell signaling and cellular growth and differentiation. Specific genetic mutations have been correlated with the development of certain forms of cancer. Payments will be made to Response Genetics upon achievement of agreed-to milestones. Further financial details were not disclosed.
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.